- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
Chapter 8
Diabetic Macular Ischemia
Scott E. Pautler
8.1 Introduction
Diabetic retinopathy encompasses many interrelated pathological changes that occur in the retina of diabetic patients. Retinal ischemia has received much attention as a primary risk factor for the development of proliferative diabetic retinopathy.1 Ischemia affecting the macula has received less attention in the literature likely due to difficulty in detection and lack of treatment options.2 Retinal capillary nonperfusion was first described by Ashton using India ink preparations of the diabetic retina (Fig. 8.1).3 Subsequent histological studies revealed acellular capillaries in zones of nonperfusion (Fig. 8.2).4–7 Clinically, diabetic macular ischemia is detected by fluorescein angiography as a lack of filling of the macular capillaries, which correlates well with reported histological changes.1,7–9 Although capillary obstruction occurs in the early stages of diabetic retinopathy, precapillary arteriolar and larger arteriolar occlusions become increasingly evident in more advanced stages.3 The cause and sequence of evolution are not well understood, but the risk factors for DMI are likely those of diabetic retinopathy in general. These include
degree and duration of hyperglycemia and hyper- tension.10–12 Small studies of DMI identify
increased risk of macular ischemia with diabetic macular edema, increased stage of diabetic retinopathy, and other factors that likely relate to severity
S.E. Pautler (*)
Department of Ophthalmology, University Community Hospital, University of South Florida, Tampa, FL 33607, USA
e-mail: pautlers@aol.com
of diabetes, such as age of onset.2,13,14 Prevalence data are not available as major population studies
of diabetic retinopathy are not geared to identify macular ischemia.15,16 Despite these gaps in under-
standing, diabetic macular ischemia is recognized as an important cause of visual disability and poor response to treatment of diabetic macular edema and proliferative diabetic retinopathy.7,17,18
8.2Pathogenesis, Anatomy, and Physiology
Anatomic changes in diabetic macular ischemia include a variety of cellular and extracellular abnormalities resulting in a loss of neuroretinal tissue and occlusion of the microvasculature. These anatomic changes occur in the late stages of diabetic retinopathy along with other complications of diabetic retinopathy, such as macular edema and fibrovascular proliferation. Thus, it is difficult to study macular ischemia in isolation. Furthermore, there are myriad physiological and anatomical alterations with complicated and arcane interactions that have not been fully elucidated to date.
Factors involved in the occlusion of macular capillaries include changes in the vascular lumen itself, as well as interactions with the extraluminal neurosensory retina and intraluminal blood constituents. Diabetes affects both the cellular and extracellular components of the retinal capillary wall. Among the earliest pathological abnormalities are alterations in the retinal capillary basement membrane, which represents the shared basement membrane of the pericytes and endothelial cells.
D.J. Browning (ed.), Diabetic Retinopathy, DOI 10.1007/978-0-387-85900-2_8, |
203 |
Springer ScienceþBusiness Media, LLC 2010 |
|
204 |
S.E. Pautler |
|
|
Fig. 8.1 India ink preparation demonstrating capillary loss in diabetic retinopathy. (Reprinted with permission from Ashton.3 Copyright # 1953 British Journal of Ophthalmology. All rights reserved)
Normally, the basement membrane is primarily composed of a thin, smooth deposition of type IV collagen with macromolecules, which interact with the endothelium. The basement membrane may serve as a skeleton to support cellular components, as a molecular sieve, and metabolically as an inhibitor of proliferation. In diabetic retinopathy, there is thickening of the retinal capillary basement membrane with increased type IV collagen deposition, vacuolization, deposition of fibrillar type III collagen, and decreased heparin sulfate BM-1 proteo- glycan.19–21 The alteration of macromolecules
within the basement membrane may result in direct deleterious effects on endothelial cells.20 The cause of these basement membrane changes appears to be related to the aldose reductase metabolic pathway, advanced glycation end products (AGE) for-
mation, and vascular endothelial growth factor (VEGF).19,21–25 Retinal cellular dysfunction may
result in the formation of abnormal basement membrane by the endothelium.23,26 Conversely, it is con-
ceivable that basement membrane pathology may be causally related to further subsequent cellular changes. For example, a thickened basement membrane may decrease access of nutrients and oxygen to pericytes and neurosensory retina in a manner analogous to thickening of Bruch’s membrane in age-related macular degeneration.27–29 Low oxygen tension induces the expression of VEGF and its receptors.25
Pericytes surround the abluminal capillary surface and play important roles in capillary function. As pericytes are derived from smooth muscle cell precursors, they may regulate vascular tone.30–32 Pericytes produce structural elements of the extracellular matrix and basement membrane.30 Pericytes
regulate endothelial proliferation and differentiation.30,33 They are well seen on enzymatic digest
preparations with prominent round nuclei on the outer surface of the capillary wall, and loss of pericytes is revealed as empty balloon-like spaces (Fig. 8.3).6 Pericyte apoptosis occurs early in diabetic retinopathy. Pericytes have a relatively lower rate of proliferation relative to endothelial cells, which are also lost through apoptosis. Consequently,
Fig. 8.2 Perifoveal acellular capillaries in diabetic retinopathy correspond to nonperfused retina. Trypsin digest with hematoxylin– eosin stain. (Reprinted with permission from Bresnick et al.7 Copyright # 1976 Elsevier. All rights reserved)
8 Diabetic Macular Ischemia |
205 |
|
|
Fig. 8.3 Flat section reveals former pericytes as clear spaces on the outer surface of the capillary wall. (Reproduced with permission from Cogan et al.5 Copyright # 1961 American Medical Association. All rights reserved)
pathological specimens often show a greater loss of pericytes relative to endothelial cells.34 A newer concept explaining the loss of pericytes is angiopoie- tin-induced migration of pericytes from the capillary wall.35 Because pericyte loss occurs to a much greater degree in the retina than in other tissues, local retinal factors are implicated in the pathogenesis.4 Additional factors implicated in pericyte loss include impaired adhesion to abnormal basement
membrane and adverse effects of hyperglycemia on cell replication.36,37 The loss of pericytes may lead
to closure of capillary lumen though the loss of cytokine interaction with the endothelium.38 The presence of antipericyte antibodies may represent a risk factor for diabetic macular ischemia; it is unknown whether this is a cause of or a result of tissue damage.39–41
The endothelial cell plays a central role in diabetic retinopathy. The endothelium interacts with
many humoral and cellular elements, and loss of endothelial cells is associated with capillary closure. The endothelium is a continuous monocellular lining of the luminal wall of retinal capillaries and with intercellular tight junctions creates a barrier to the diffusion of macromolecules (the blood–ocular barrier). Its function is affected by surrounding ele-
ments in the capillary wall, the neurosensory retina, and the blood components.23,26,38 The molecular
mechanisms involved in endothelial damage and macular ischemia are complex and include the sorbitol pathway, AGE formation, protein kinase C, renin–angiotensin system, inflammation, oxidation,
and alterations in gene expression and in the release of numerous cytokines.42–54 There may be a balance
of angiogenic cytokines, which appear to protect against apoptosis of the endothelium, and anti-
angiogenic cytokines, which may induce apoptosis.55,56 In diabetes, factors in the blood stream
that lead to endothelial damage include increased platelet aggregation and adherence, as well as leukostasis resulting from less deformability, increased activation, and increased adhesion.57–61 Decreased red blood cell deformability and increased aggregation occur with hyperglycemia as well.62 Normal platelet–endothelial interaction maintains the endothelial vascular integrity through the release of humoral factors that stabilize the tight junctions.33 Platelets also mediate endothelial–leuko- cyte interaction and help suppress blood–ocular breakdown when the endothelium becomes damaged.63,64 The degradation of extracellular matrix in diabetic retinopathy releases fibronectin and associated fragments that stimulate endothelial cell proliferation and adhesion, likely involved in microaneurysm formation and neovascularization.65 Endothelial cell proliferation may play a role in the pathogenesis of microaneurysms, and hypertrophy may result in capillary occlusion.66 Subsequent apoptosis of the endothelium may also result in obliteration of the capillary lumen and neurosensory nonperfusion.7,9,34 Platelet–fibrin thrombi likely contribute to obliteration of the capillary lumen in association with endothelial cell loss.67 Integrin-mediated leukocyte entrapment is increasingly recognized as a cause of arteriolar occlusion and downstream damage to the capillary bed.68–71 Following acute occlusion, retinal glial cells invade and proliferate within the vascular lumen.72
206 |
S.E. Pautler |
|
|
The Role of VEGF in the Early and Late Stages of Diabetic Retinopathy
VEGF is one of many cytokines that plays a prominent role in diabetic retinopathy and is induced by ischemic neurosensory retina.73,74 VEGF is a marker of oxidative stress and induces hyperpermeability of macular capillaries contributing to macular edema.75–77 VEGF also induces endothelial proliferation and migration consistent with clinical findings of microaneurysm and neovascular membrane formation.53 VEGF prevents apoptosis of capillary endothelial cells.56 When neurosensory cell death occurs, VEGF production might be expected to decrease with the result of apoptotic endothelial cell loss, capillary occlusion, resolution of macular edema, and involution of neovascularization. Indeed, this clinical picture is seen late in the course of diabetic retinopathy.78,79 In addition, VEGF offers protection against apoptotic neuroretinal cell death in ischemic retinal conditions.80 This raises concern regarding the use of multiple injections of anti-VEGF agents in the treatment of eyes with ischemic diabetic retinopathy.81 The possibility exists that anti-VEGF therapy may help preserve vision in the short term by reducing macular edema and proliferative complications at the long-term expense of eventual neuroretinal apoptosis and capillary dropout. Supporting this hypothesis is the finding that intravitreal bevacizumab (IVB) injections for diabetic macular edema (DME) may result in a decrease in visual acuity in eyes with macular ischemia despite a decrease in macular thickness/edema.81 Also, a case report demonstrated the acute loss of vision and rapid enlargement of the FAZ following IVB injection in an eye with diabetic macular ischemia.82 In another report, IVB for severe PDR with traction retinal detachment resulted in acute loss of vision to no light perception.83 However, in a retrospective case series of DME treated with multiple IVB injections, no progressive change in FAZ diameter was reported.84 Furthermore, in a small prospective clinical trial of bevacizumab for DME in eyes with severe macular ischemia, no change in perfusion was detected over a 1-year follow-up period.85 Indeed, some researchers reported subtle evidence of limited improvement in perfusion of the retina following bevacizumab injection,
though this apparent change may be due to a reversal of shunting of blood flow through neovascular channels in PDR.83,86,87 Additional research is needed to better define the role of VEGF in diabetic
retinopathy.
There is evidence to suggest that the neurosensory retina plays a role in the evolution of retinal microangiopathy.88 Prior to the development of diabetic retinopathy, neurosensory retinal dysfunction is evident on testing with ERG, hue discrimination, and contrast sensitivity.89–97 Early functional
changes in neurotransmission are reversible and may be due to hyperglycemia or hypoxia.92,98,99
Although there is an adaptive response by the retina to hyperglycemia, over time permanent neurosen-
sory damage occurs and may lead to further microvascular changes of diabetic retinopathy.90,100–102
For example, the hypoxic retina produces VEGF,
among other cytokines, in response to hypoxia.73,103,104 VEGF production may represent
an adaptive response to metabolic stress in order to promote neuronal survival.88 VEGF protects
against apoptosis and induces endothelial proliferation, migration, and vasopermeability that may
lead to microaneurysm formation, neovascularization, and edema.53,56,105 Glutamate excitotoxic
damage may ultimately lead to neurosensory apoptosis leading to a reduction in cytokine production and resultant retinal capillary cellular apoptosis and capillary closure.89,106 In addition, lipid mediators are released from the neurosensory retina in response to oxidative stress. These prostanoids contribute to neurovascular injury and
directly induce endothelial cell death with subsequent closure of the capillary bed.67,107 Thus, a
number of pathways have been identified to support the role of neurosensory damage in contributing to capillary dropout. In addition, there are examples of retinal vasculopathy secondary to
